The results were stark: one year after all treatment was stopped, the researchers found no detectable virus and no antiviral immune response, indicating permanent clearance.

Key experimental findings from the published paper:

• No single agent worked alone. Prior experiments showed that ART, bNAbs alone, and leronlimab alone each failed to prevent viral reservoir establishment. Leronlimab alone did reduce reservoir seeding in lymphoid and gastrointestinal tissues, but could not clear the infection .
• The combination was decisive. When all three agents were given together at 72 hours post-infection, no evidence of replicating or latent virus remained .
• Proposed mechanism: ART suppresses active viral replication; bNAbs neutralize free virus circulating in the blood; leronlimab blocks residual HIV from entering immune cells by sealing off the CCR5 co-receptor. The three mechanisms together appear to starve the nascent viral reservoir of new target cells before it can establish .

Potential Implications for Human Neonatal Treatment

This study offers the first proof-of-concept in primates that a finite, early intervention can prevent reservoir establishment — a fundamentally different goal from lifelong ART, which only controls viral replication .

Pathway to clinical trials: ART is already approved for use in human newborns. Both bNAbs and leronlimab are in separate human clinical trials for other indications. The research team expects to test the combination first in newly exposed adults, then in newborns, following standard safety and dose-finding protocols .

Global relevance: Approximately 120,000 infants contract HIV perinatally each year . A single, one-time regimen given within days of birth could transform neonatal HIV from a lifelong chronic disease into a potentially curable condition — especially for the millions of children in low-resource settings who lack consistent access to lifelong ART .

Remaining Unanswered Questions

Despite the breakthrough results, significant questions remain before this approach can reach human patients:

• Mechanism is not fully understood. The precise synergy among the three agents, and why CCR5 blockade is so critical in this narrow treatment window, is still unclear .
• Time window limits. The 72-hour post-exposure window has not been tested beyond three days. It is unknown whether the regimen would work at one week or two weeks after infection .
• Adult applicability. It remains unknown whether the same approach can clear infection in adults, whose immune systems and viral reservoirs are more established .
• No human data yet. Safety, optimal dosing, efficacy, and durability of the combination in humans are all open questions awaiting clinical trials .
• Access and delivery challenges. The narrow 72-hour window requires rapid diagnosis of neonatal HIV exposure and immediate access to advanced biologics — a major hurdle in the low-resource settings where most pediatric HIV occurs.

Broader Implications for the HIV Epidemic

Pediatric elimination goal: If proven in humans, this regimen could functionally eliminate mother-to-child HIV transmission as a source of lifelong infection — a long-standing priority for the WHO and UNAIDS .

Proof of concept for cure strategies: This is the first demonstration that a finite, early intervention can prevent reservoir establishment in primates, opening the door to similar "hit early and hard" approaches in adults .

Shift in research focus: The results validate CCR5 blockade (via leronlimab) as a critical third pillar alongside ART and bNAbs, potentially reshaping combination cure research agendas .

Limits remain: Even if the approach works in humans, it does not address the approximately 38 million people already living with HIV, nor does it solve prevention, vaccine, or access challenges. The regimen's complexity and cost may also limit deployment in the highest-burden regions .

Bottom line: This is a landmark nonhuman primate study showing that a one-time triple regimen given within 72 hours can permanently clear HIV — a result no single therapy has ever achieved. Human trials are the urgent next step, and the approach could fundamentally alter the landscape of pediatric HIV if safety and efficacy are confirmed .

The results were stark: one year after all treatment was stopped, the researchers found no detectable virus and no antiviral immune response, indicating permanent clearance.

Key experimental findings from the published paper:

• No single agent worked alone. Prior experiments showed that ART, bNAbs alone, and leronlimab alone each failed to prevent viral reservoir establishment. Leronlimab alone did reduce reservoir seeding in lymphoid and gastrointestinal tissues, but could not clear the infection .
• The combination was decisive. When all three agents were given together at 72 hours post-infection, no evidence of replicating or latent virus remained .
• Proposed mechanism: ART suppresses active viral replication; bNAbs neutralize free virus circulating in the blood; leronlimab blocks residual HIV from entering immune cells by sealing off the CCR5 co-receptor. The three mechanisms together appear to starve the nascent viral reservoir of new target cells before it can establish .

Potential Implications for Human Neonatal Treatment

This study offers the first proof-of-concept in primates that a finite, early intervention can prevent reservoir establishment — a fundamentally different goal from lifelong ART, which only controls viral replication .

Pathway to clinical trials: ART is already approved for use in human newborns. Both bNAbs and leronlimab are in separate human clinical trials for other indications. The research team expects to test the combination first in newly exposed adults, then in newborns, following standard safety and dose-finding protocols .

Global relevance: Approximately 120,000 infants contract HIV perinatally each year . A single, one-time regimen given within days of birth could transform neonatal HIV from a lifelong chronic disease into a potentially curable condition — especially for the millions of children in low-resource settings who lack consistent access to lifelong ART .

Remaining Unanswered Questions

Despite the breakthrough results, significant questions remain before this approach can reach human patients:

• Mechanism is not fully understood. The precise synergy among the three agents, and why CCR5 blockade is so critical in this narrow treatment window, is still unclear .
• Time window limits. The 72-hour post-exposure window has not been tested beyond three days. It is unknown whether the regimen would work at one week or two weeks after infection .
• Adult applicability. It remains unknown whether the same approach can clear infection in adults, whose immune systems and viral reservoirs are more established .
• No human data yet. Safety, optimal dosing, efficacy, and durability of the combination in humans are all open questions awaiting clinical trials .
• Access and delivery challenges. The narrow 72-hour window requires rapid diagnosis of neonatal HIV exposure and immediate access to advanced biologics — a major hurdle in the low-resource settings where most pediatric HIV occurs.

Broader Implications for the HIV Epidemic

Pediatric elimination goal: If proven in humans, this regimen could functionally eliminate mother-to-child HIV transmission as a source of lifelong infection — a long-standing priority for the WHO and UNAIDS .

Proof of concept for cure strategies: This is the first demonstration that a finite, early intervention can prevent reservoir establishment in primates, opening the door to similar "hit early and hard" approaches in adults .

Shift in research focus: The results validate CCR5 blockade (via leronlimab) as a critical third pillar alongside ART and bNAbs, potentially reshaping combination cure research agendas .

Limits remain: Even if the approach works in humans, it does not address the approximately 38 million people already living with HIV, nor does it solve prevention, vaccine, or access challenges. The regimen's complexity and cost may also limit deployment in the highest-burden regions .

Bottom line: This is a landmark nonhuman primate study showing that a one-time triple regimen given within 72 hours can permanently clear HIV — a result no single therapy has ever achieved. Human trials are the urgent next step, and the approach could fundamentally alter the landscape of pediatric HIV if safety and efficacy are confirmed .